Cargando…
Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis
OBJECTIVE: To ascertain if etoricoxib increases the risk of gastrointestinal adverse events (GAEs) compared with placebo, diclofenac, and naproxen in the treatment of patients with osteoarthritis (OA) or rheumatoid arthritis (RA). METHODS: Studies were searched in MEDLINE, EMBASE, Cochrane Central R...
Autores principales: | Feng, Xiaoting, Tian, Mei, Zhang, Wei, Mei, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761870/ https://www.ncbi.nlm.nih.gov/pubmed/29320568 http://dx.doi.org/10.1371/journal.pone.0190798 |
Ejemplares similares
-
Etoricoxib for arthritis and pain management
por: Brooks, Peter, et al.
Publicado: (2006) -
A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]
por: Collantes, Eduardo, et al.
Publicado: (2002) -
Do etoricoxib and indometacin have similar effects and safety for gouty arthritis? A meta-analysis of randomized controlled trials
por: Lin, Tzu-Min, et al.
Publicado: (2018) -
Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis
por: Cheng, Bai-Ru, et al.
Publicado: (2021) -
Etoricoxib prevents progression of osteolysis in repeated intra-articular monosodium urate-induced gouty arthritis in rats
por: Lin, Yen-You, et al.
Publicado: (2020)